Activation of Janus kinase 1 confers poor prognosis in patients with non-small cell lung cancer.
Activation of Janus kinase 1 confers poor prognosis in patients with non-small cell lung cancer.
复制标题
DOI：
10.3892/ol.2017.6690
复制
发表时间：
2017-10
期刊：
影响因子：
2.9
通讯作者：
Li L
中科院分区：
文献类型：
--
作者：
Liu D;Huang Y;Zhang L;Liang DN;Li L
据报道，Janus激酶1（JAK 1）的激活发生在非小细胞肺癌（NSCLC）中，激活JAK/信号转导子和转录激活子级联反应。然而，JAK 1激活与NSCLC预后价值之间的关系仍不清楚。本研究初步探讨了JAK 1活化形式（p-JAK 1）的表达与NSCLC患者预后之间的关系。分析了142个切除的原发性NSCLC组织样本的队列，包括74个腺癌（ADCC）和68个鳞状细胞癌样本。免疫组化法检测p-JAK 1表达状态。随后在74例ADCC样本中通过荧光原位杂交评估表皮生长因子受体（EGFR）基因扩增。采用单因素和多因素生存分析评价p-JAK 1表达和EGFR基因扩增的预后意义。p-JAK 1在NSCLC组织中的表达明显高于正常肺组织（P<0.001）。p-JAK 1阳性表达提示预后不良，尤其是早期患者（I/II期，包括肿瘤大小<3cm，淋巴结浸润N 0/1;均P<0.05）。p-JAK 1表达是预后不良的独立预测因子（P=0.022）。p-JAK 1阳性表达和EGFR扩增肿瘤患者的总生存时间与肿瘤一种或两种特征均阴性的患者相比显著缩短（两种特征均存在vs.两种特征均不存在，P<0.001）。本研究结果为JAK 1的激活是独立的预后因素提供了临床证据，尤其是在早期NSCLC中。EGFR基因扩增和p-JAK 1表达的联合检测可能成为NSCLC个体化治疗策略选择和疗效预测的新靶点。
The activation of Janus kinase 1 (JAK1) has been reported to occur in non-small cell lung cancer (NSCLC), activating the JAK/signal transducers and activators of transcription cascade. However, the association between JAK1 activation and the prognostic value in NSCLC remains unclear. The present study initially investigated the association between expression of the activated form of JAK1 (p-JAK1) and prognosis in patients with NSCLC. A cohort of 142 resected primary NSCLC tissue samples, including 74 adenocarcinoma (ADCC) and 68 squamous cell carcinoma samples, were analyzed. p-JAK1 expression status was determined by immunohistochemistry. Evaluation of epidermal growth factor receptor (EGFR) gene amplification by fluorescence in situ hybridization was subsequently performed in 74 ADCC samples. The prognostic significance of p-JAK1 expression and EGFR gene amplification were evaluated with univariate and multivariate survival analyses. Compared with normal lung tissue, p-JAK1 expression level was significantly increased in NSCLC (P<0.001). Positive p-JAK1 expression indicated a poor prognosis, particularly for patients in early stages (stage I/II, including tumor size <3 cm, Lymph node invasion N0/1; all P<0.05). p-JAK1 expression was an independent predictor of a poor prognosis (P=0.022). The overall survival time for patients with positive p-JAK1 expression and EGFR-amplified tumors was significantly shortened compared with patients with tumors negative for one or both features (both features present vs. neither feature present, P<0.001). The results provided clinical evidence that the activation of JAK1 was an independent prognostic factor, particularly in early stage NSCLC. The combination of EGFR gene amplification and p-JAK1 expression may be a novel target for the selection of individual therapy strategies and predicting the effects of therapy for NSCLC.
登录
查看更多内容
影响因子：
2.9
作者：
Gurbuz V;Konac E;Varol N;Yilmaz A;Gurocak S;Menevse S;Sozen S
通讯作者：
Sozen S
影响因子：
2.4
作者：
Koh, Youngil;Jang, Bogun;Heo, Dae Seog
通讯作者：
Heo, Dae Seog
影响因子：
6.2
作者：
Liu, Dan;Huang, Yi;Li, Weimin
通讯作者：
Li, Weimin
影响因子：
50.5
作者：
Peters, S.;Adjei, A. A.;Felip, E.
通讯作者：
Felip, E.
影响因子：
3.7
作者：
Bergmann, Anke K.;Schneppenheim, Sina;Siebert, Reiner
通讯作者：
Siebert, Reiner